Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications "Central to our strategy is the development of a fully integrated regenerative platform spanning manufacturing, clinical validation, and commercial execution," said Lance Alstodt, BioRestorative Therapies Chief Executive Officer. "Exosomes and other extracellular vesicle-based biologics represent a foundational component of that platform, with applicability ac ...